IDiyas

For the Inventor, By the Inventor

Tokyo, Japan

Yasuteru Iijima

USPTO Granted Patents = 16

Average Co-Inventor Count = 5.5

ph-index = 3

Forward Citations = 41(Granted Patents)


Location History:

  • Hiromachi, JP (1988 - 1996)
  • Tokyo, JP (1993 - 1998)
  • Funabashi, JP (2009)

Company Filing History:

goldMedal15 out of 613 
 
Sankyo Company, Limited
 patents
silverMedal1 out of 1 
 
Sankko Company, Limited
 patent

Years Active: 1988-2009

Loading Chart...
16 patents (USPTO):Explore Patents
1. 7592140 - 2', 5′-oligoadenylate phosphodiesterase (2009-09-22),
2. 5760042 - Griseolic acid derivatives, their preparation and their use (1998-06-02),
3. 5616600 - Griseolic acid compounds and their use as a phosphodiesterase inhibitor (1997-04-01),
4. 5559109 - Method of treating a PAF-mediated pathology or for treating or (1996-09-24),
5. 5556975 - Griseolic acid derivatives (1996-09-17),
6. 5556852 - N-acryloylpiperazine compounds (1996-09-17),
7. 5532369 - Intermediates for griseolic acid derivatives (1996-07-02),
8. 5498819 - Griseolic acid derivatives, their preparation and their use (1996-03-12),
9. 5470851 - Thiazolidinecarboxylic acid amide derivatives and their therapeutic uses (1995-11-28),
10. 5378690 - New renin-inhibitory oligopeptides, their preparation and their use (1995-01-03),
11. 5378689 - Peptides having renin inhibitory activity, their preparation and use (1995-01-03),
12. 5369106 - N-acryloylpiperazine derivatives, their preparation and their use of PAF (1994-11-29),
13. 5364844 - Renin-inhibitory oligopeptides, their preparation and use (1994-11-15),
14. 5192766 - N-acryloylpiperazine derivatives, their preparation and their use as PAF (1993-03-09),
15. 4778790 - Perhydrothiazepine and perhydroazepine derivatives and their therapeutic (1988-10-18),

Title: The Innovative Contributions of Yasuteru Iijima in Biotechnology

Introduction

Yasuteru Iijima is a noteworthy inventor based in Tokyo, Japan, renowned for his significant contributions to the field of biotechnology. With a remarkable portfolio of 16 patents, Iijima has been at the forefront of innovations aimed at advancing medical therapies, particularly in the areas of viral infections and tumor treatments.

Latest Patents

Among Iijima's latest patents, two stand out for their potential therapeutic applications. The first patent focuses on 2',5'-oligoadenylate phosphodiesterase, detailing polypeptides that possess this activity, along with the corresponding antibodies and polynucleotides coding for these polypeptides. This innovation also covers recombinant plasmid DNAs containing the polynucleotides and host cells transformed by these plasmids. These advancements are critical for screening substances that inhibit the activity and expression of 2',5'-oligoadenylate phosphodiesterase, which can lead to the discovery of new therapeutic agents for treating viral infections and tumors.

The second patent he developed relates to novel griseolic acid derivatives, which feature various groups substituted in the sugar part instead of the adenine group of griseolic acid. These compounds, which are primarily purine derivatives or analogs, show promise as potent phosphodiesterase inhibitors, potentially expanding the therapeutic arsenal available for various diseases.

Career Highlights

Iijima's illustrious career includes significant tenures at prominent companies such as Sankyo Company, Limited and Sankko Company, Limited. His work at these institutions has heavily influenced advancements in drug development and biotechnology.

Collaborations

Throughout his career, Iijima has collaborated with other notable scientists, including Hiroyuki Koike and Takeshi Oshima. These collaborations have fostered an environment of innovation and have contributed to the successful development of numerous patents and therapies.

Conclusion

Yasuteru Iijima's innovative work in biotechnology has positioned him as a key figure in the quest for effective treatments for viral infections and tumors. His extensive patent portfolio reflects his commitment to advancing science and medicine, demonstrating the vital role that inventors like him play in shaping the future of healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…